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Background: Chronic inflammatory airway disease (CIAD) has emerged as independent risk factor for cardiovascular
mortality and ischemic stroke but the impact of co-existing CIAD in patients with ischemic stroke is less clear.
Methods: We retrospectively analyzed 1013 patients with acute ischemic stroke who were consecutively admitted to
the Department of Neurology, Charité - Universitätsmedizin Berlin, Germany within one year. Mean follow-up was
80 months (IQR 32–85 months). Using multivariable regression models we analyzed the impact of CIAD (defined as
chronic obstructive pulmonary disease or asthma bronchiale) on stroke severity and outcome.
Results: Co-existing CIAD was evident in 7.1 % (n = 72) of all patients with acute ischemic stroke. Baseline characteristics
of stroke patients with CIAD did not differ significantly from ischemic stroke patients without CIAD. Age (OR 1.17 [95 % CI
1.03-1.37] per decade), atrial fibrillation (OR 3.43 [95 % CI 2.47-4.78]) and coronary artery disease (OR 1.51 [95 % CI
1.07–2.14]) but not a history of CIAD (p = 0.30) were associated with severe stroke (NIHSS≥11) on hospital
admission. Age (HR 1.70 [95 % CI 1.53-1.87] per decade), peripheral artery disease (HR 1.91 [95 % CI 1.35-2.7]),
stroke severity at hospital admission (NIHSS per point HR 1.08 [95 % CI 1.06-1.10]), and history of CIAD (HR 1.43
[95 % CI 1.02-2.00]) were independently associated with mortality during long-term follow-up. However, CIAD was
not significantly associated with short-term mortality after stroke.
Conclusion: Co-existing CIAD showed no significant association with stroke severity at hospital admission and
early mortality after ischemic stroke. CIAD was negatively associated with long-term survival after ischemic stroke.Background
Chronic inflammatory airway disease (CIAD) and ische-
mic stroke are both primarily affecting the elderly, and
their prevalence is expected to rise in the near future.
Even today, CIAD as well as ischemic stroke are leading
causes of morbidity and mortality worldwide [1, 2]. In
addition to the risk profile that CIAD and ischemic
stroke have in common, available data indicate that
CIAD itself increases the odds of having a stroke about
1.1- to 3.8-fold [3–8]. Various interrelated mechanisms
may contribute to an increased stroke risk in CIAD-
patients, i.e. chronic infection promoting large-artery* Correspondence: georg.haeusler@charite.de
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thrombocyte aggregation, and atrial fibrillation [9–11].
The CIAD related mortality is likely underestimated
because of the difficulties to identify the cause of
death [12]. The severity of CIAD, advanced age and
smoking may have an impact on the stroke risk of
CIAD-patients [4, 13, 14].
The interaction of CIAD and stroke outcome is less
well understood. A history of stroke was related to an
increased in-hospital mortality in patients with exacer-
bated CIAD in a recent cross-sectional multicenter study
[15]. In addition, stroke-associated death was inversely
co-related to the forced expiratory volume within a pro-
spective general population study [16]. Furthermore,
CIAD is an independent risk factor for pneumonia after
stroke [17], and, in turn, pneumonia is a major cause ofle is distributed under the terms of the Creative Commons Attribution 4.0
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of epidemiological data regarding the frequency and im-
pact of CIAD on acute stroke severity and long-term
outcome after stroke.
The aims of this post-hoc study were: (I) to analyze
the frequency of CIAD in patients with acute ischemic
stroke; (II) to identify whether a history of CIAD is a
relevant risk factor for the severity of acute ischemic
stroke; (III) to investigate the impact of co-existing
CIAD on survival after acute ischemic stroke.
Methods
Study design and study population
The retrospective study was conducted at the Department
of Neurology, Charité - Universitätsmedizin Berlin and
approved by the Charité Ethics Committee (EA1/186/
07), waiving the need for obtaining informed consent.
After defining the hypothesis of CIAD as an impact fac-
tor on outcome after ischemic stroke, medical records
of all patients with acute ischemic stroke or TIA admit-
ted to the three university hospitals of the Charité,
Berlin, Germany, between 1st January and 31st Decem-
ber 2004 were analyzed retrospectively. Stroke or TIA
patients were identified by using relevant ICD-10 dis-
charge diagnoses (I61.x; I63.x; G45.x). All patients with
ischemic stroke were included in the primary analysis.
Additional analysis was performed combining patients
with ischemic stroke and TIA. The following informa-
tion was assessed from medical records: demographic
details, medical history, antithrombotic medication and
cardiovascular risk factors (e.g. atrial fibrillation, congestive
heart failure, CIAD, hypertension, diabetes mellitus, previ-
ous stroke or TIA, intracerebral hemorrhage or non-stroke
vascular events). Coexisting CIAD was defined as chronic
obstructive pulmonary disease or asthma bronchiale and
each diagnosis was identified from the medical records.
Furthermore, in one patient presence of anti-obstructive
medication (fluticasone and salmeterol) was taken into ac-
count. Stroke severity was assessed on admission according
to the National Institutes of Health Stroke Scale (NIHSS)
score [19].
Stroke severity was defined as “mild to moderate
stroke” (NIHSS <11 points) and “severe stroke”
(NIHSS ≥11 points) [20]. Functional status of patients
on hospital admission was further assessed by the
modified Rankin Scale (mRS) [21]. All patients were
prospectively followed-up on survival status for up
to 8 years after the index stroke. Survival status
was obtained from the German central civil regis-
tration office. All patients without available survival
status (because of an invalid address or registration)
were excluded from survival analysis. All-cause
mortality during follow-up was defined as the
primary endpoint. “Short-term” mortality was definedas death ≤ 90 days after the index stroke, while “long-
term” mortality was defined as death >90 days after
stroke. We do not have detailed information on cause
of death after hospital discharge.Statistical analysis
For categorical variables, absolute and relative frequencies
were reported. In the case of continuous variables with
normal distribution, the mean and standard deviation was
reported. If continuous variables were non-normally dis-
tributed, the median and limits of interquartile range were
reported. Distribution of variables was tested for normality
using the Kolmogorov-Smirnov test. The χ2-test was used
to test differences in proportions for dichotomous vari-
ables between independent groups. A linear trend test was
used to analyze ordinal data. The Mann–Whitney-U-test
was applied to analyze not normally distributed variables
and multivariable logistic regression was applied as appro-
priate. Odds ratios (OR) with 95 % confidence intervals
(CI) are reported for characteristics associated with stroke
severity according to the NIHSS score or survival, respect-
ively. Stepwise multivariable analysis was performed
including all parameters with significant association to
outcome according to bivariate analyses. Survival analyses
were performed at 30 days, 90 days, and for the entire
follow-up period. Cox proportional hazards analysis and
log-rank test (Mantel Cox) were used for survival analyses.
Hazard ratios (HR) and 95 % confidence intervals (CI) are
presented. Multivariable analysis was performed with all
parameters that showed significant associations in bivari-
ate analyses using the enter method to ensure CIAD was
included in the model. The survival function was esti-
mated by the Kaplan-Meier method (product-limit estima-
tor). A p-value of <0.05 was considered to be significant.
No adjustment for multiple testing was applied. Data were
analyzed using SPSS statistics 22.Results
We included 1013 consecutive patients with acute ische-
mic stroke during the outlined enrolment period. Mean
age was 68.1 ± 13.4 years, 474 patients (46.8 %) were fe-
male and 243 patients (24.0 %) had suffered a stroke prior
to the index stroke. Median NIHSS of all patients was 4
(IQR 2 – 10) on admission. Further baseline characteris-
tics (co-morbidities, disability on admission, antithrom-
botic medication before admission) are shown in Table 1.
During the in-hospital stay 37 (3.7 %) stroke patients died
(median: 5.0 days after admission (IQR 2.0 - 7.5). Further-
more, 213 TIA patients were identified. Mean age of these
patients was 68.3 ± 12.6 years, 108 patients (50.7 %) were
female and 38 patients (17.8 %) had a stroke prior. None
of these patients died in-hospital.
Table 1 Baseline characteristics of all 1013 patients with ischemic stroke, and of those with (n = 72) or without CIAD (n = 941),
respectively
All stroke patients n = 1013 Stroke patients without CIAD n = 941 Stroke patients with CIAD n = 72 p*
Age; median (IQR) 69.0 (61.0–78.0) 69.0 (60.0–78.0) 73.0 (65.3–78.8) 0.042
Female sex; % (n) 46.8 (474) 47.0 (442) 44.4 (32) 0.679
Comorbidities; % (n)
Previous stroke or TIA 24.0 (243) 24.0 (226) 23.6 (17) 0.938
Atrial fibrillation 26.5 (268) 26.0 (245) 31.9 (23) 0.273
Diabetes 28.0 (284) 27.5 (259) 34.7 (25) 0.190
Hypertension 71.8 (727) 71.6 (674) 73.6 (53) 0.718
Coronary artery disease 21.6 (219) 21.0 (198) 29.2 (21) 0.106
Peripheral artery disease 6.0 (61) 5.7 (54) 9.7 (7) 0.171
Chronic heart failure 16.6 (168) 16.5 (155) 18.1 (13) 0.728
Mechanical heart valve 0.4 (4) 0.4 (4) 0.0 (0) 0.579
NIHSS† score; % (n) 0.169
0 – 10 points 75.9 (769) 76.3 (718) 70.8 (51)
≥ 11 points 24.1 (244) 23.7 (223) 29.2 (21)
Modified Rankin Scale score; % (n) 0.080
0–1 16.9 (171) 17.4 (164) 9.7 (7)
2–3 47.5 (481) 47.5 (447) 47.2 (34)
4–5 35.6 (361) 35.1 (330) 43.1 (31)
Antithrombotic medication prior to admission; % (n) 0.370
None 66.4 (672) 65.9 (619) 73.6 (53)
Antiplatelets 28.8 (291) 29.5 (277) 19.4 (14)
Vitamin K antagonist 4.0 (40) 3.7 (35) 6.9 (5)
Vitamin K antagonist & antiplatelet 0.3 (3) 0.3 (3) 0.0 (0)
Heparin, full-dose 0.5 (5) 0.5 (5) 0.0 (0)
Heparin, full-dose & antiplatelet 0.1 (1) 0.1 (1) 0.0 (0)
Thrombolysis with rt-PA; % (n) 7.8 (79) 7.7 (72) 9.7 (7) 0.351
In-hospital mortality; % (n) 3.7 (37) 3.6 (34) 4.2 (0) 0.742
*p values CIAD patients vs. patients without CIAD; based on Fishers’ exact test, linear trend test or exact Mann–Whitney test, respectively; †National Institutes of Health
Stroke Scale. Bold indicates significant results
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Overall, 72 (7.1 %) of all stroke patients in this cohort
had a medical history (n = 57) or an in-hospital diagno-
sis of CIAD (n = 16). No significant differences were ob-
served between stroke patients with and without CIAD
regarding gender, stroke type, main co-morbidities,
prior medication or in-hospital mortality (Table 1).
However, stroke patients with CIAD were slightly older
(67.9 ± 13.5 vs. 71.0 ± 11.0, respectively; p = 0.042) and
had a higher mRS on admission (median mRS 3 (IQR
2–5) vs. 3 (IQR 2–4); p = 0.047). Median NIHSS on ad-
mission of all stroke patients with or without CIAD was
5.0 (IQR 3.0 – 11.8) or 4.0 (IQR 2.0 – 10.0), respectively
(p = 0.053). The prevalence of CIAD was similar in pa-
tients with TIA (7.4 %).Predictors for ischemic stroke severity on admission
On hospital admission, 24.1 % (n = 244) of all patients
with ischemic stroke had a NIHSS ≥ 11 indicating severe
stroke. In bivariate analysis, older age, female sex, co-
existing atrial fibrillation, heart failure as well as coron-
ary artery disease were associated with severe stroke
(Table 2), while there was no impact of CIAD (OR 1.33
[95 % CI 0.78-2.25; p = 0.30). In multivariable analysis,
age (OR 1.17 [95 % CI 1.03-1.37] per decade), a history
of atrial fibrillation (OR 3.43 [95 % CI 2.47-4.78]) and
coronary artery disease (OR 1.51 [1.07-2.14]) were inde-
pendently associated with stroke severity on admission.
When all patients with TIA (n = 213) were included
in the multivariable analysis, age (OR 1.14 [95 % CI
1.01-1.30] per decade), a history of atrial fibrillation
Table 2 Characteristics associated with stroke severity on hospital admission in 1013 patients with acute ischemic stroke (bivariate
and multivariable analyses)
Bivariate analyses Multivariable analysis
Mild to moderate stroke
(NIHSS < 11) n = 769
Severe stroke
(NIHSS≥ 11) n = 244
p value Probability severe stroke
OR (95 % CI)
p value
Age in years; median (IQR) 68.0 (59.5–77.0) 74.0 (65.0–81.0) <0.001 1.17 (1.03–1.37)* 0.018
Female sex; % (n) 44.6 (343) 53.7 (131) 0.013 1.16 (0.84–1.59) 0.372
Comorbidities; % (n)
Previous stroke or TIA 24.3 (187) 23.0 (56) 0.663
Atrial fibrillation 19.1 (147) 49.6 (121) <0.001 3.43 (2.47–4.78) <0.001
Diabetes 27.8 (214) 28.7 (70) 0.794
Hypertension 71.9 (553) 71.3 (174) 0.856
Coronary artery disease 18.9 (145) 30.3 (74) <0.001 1.51 (1.07–2.14) 0.020
Peripheral artery disease 6.0 (46) 6.1 (15) 0.924
Chronic heart failure 13.7 (105) 25.8 (63) <0.001 1.33 (0.89–1.97) 0.161
Chronic inflammatory airway disease 6.6 (51) 8.6 (21) 0.296
Antithrombotic medication prior to admission; % (n) 0.631
None 66.8 (514) 65.0 (158)
Antiplatelets 28.0 (215) 31.3 (76)
Anticoagulation INR < 2 2.6 (20) 1.6 (4)
Anticoagulation INR≥ 2† 2.6 (20) 2.1 (5)
*OR are related to age in decades; †or full-dose heparin (n = 5). Bold indicates significant results
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(OR 1.47 [CI 95 % 1.01-2.15]) were associated with
higher stroke severity, while coronary artery disease
(OR 1.40 [CI 95 % 0.99-1.98]) was not. Again, there was
no significant association of CIAD (OR 1.31 [CI 95 %
0.78-2.18]; p = 0.31) with stroke severity on admission in
this cohort of 1226 patients with ischemic stroke or TIA.
Predictors for death in stroke patients
Follow-up data for 892 stroke patients (88.1 %) and 180
TIA patients (84.5 %) were available. Overall, 383 of 892
stroke patients (42.3 %) died during follow-up (median
follow up: 80.0 months, IQR 32.0-85.0 months). MedianBA
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infection-associated death during the in hospital stay in
patients with or without CIAD, respectively.
According to log-rank-test, co-existing CIAD was associ-
ated with death during long-term follow-up in patients with
ischemic stroke (p = 0.009) as well as in patients with ische-
mic stroke or TIA (n = 1071, p = 0.036) (Fig. 1a and b)
but not in TIA patients (n = 179; p = 0.469) (Fig. 1c). In
multivariable analysis, age (HR 1.70 [95 % CI 1.53-1.87]
per decade), peripheral artery disease (HR 1.91 [95 % CI
1.35-2.71]), and stroke severity on admission (NIHSS per
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ated with death in long-term follow-up (Table 3). After
including all patients with TIA and available follow-up
in the analysis; age (HR 1.69 [95 % CI 1.54-1.85] per
decade), coronary artery disease (HR 1.30 [95 % CI
1.04-1.62]), peripheral artery disease (HR 1.79 [95 % CI
1.28-2.49]), and stroke severity on admission (NIHSS
per point HR 1.08 [95 % CI 1.06-1.10]) were associated
with long-term mortality. There was a non-significant
trend for lower long-term survival in stroke or TIA pa-
tients with CIAD according to multivariable analysis
(HR 1.32 [95 % CI 0.96-1.81]; p = 0.093).
While age, stroke severity on admission as well as co-
existing peripheral artery disease were significantly asso-
ciated with mortality during short- (30 or 90 days after
stroke onset; Table 4) and long-term follow-up (Table 3),
co-existing CIAD was significantly associated with mor-
tality only in the long term follow-up.
Discussion
This study demonstrated that co-existing CIAD is a fre-
quent co-morbidity in patients with acute ischemic
stroke. The main finding of this study is that CIAD was
not significantly associated with stroke severity at hos-
pital admission or with short-term outcome in stroke
patients. In the long-term course after ischemic stroke,
however, CIAD could be identified as a potentialTable 3 Characteristics associated with long-term mortality in patien
80 months (IQR 32–85)
Bivariate analysis
Survival n = 509 Dea
Age in years; median (IQR) 65.0 (56.5–73.0) 75.0
Female sex; % (n) 45.0 (229) 51.2
Comorbidities; % (n)
Previous stroke or TIA 20.6 (105) 30.0
Atrial fibrillation 21.8 (111) 41.0
Diabetes 23.0 (117) 36.0
Hypertension 70.1 (357) 76.5
Coronary artery disease 16.1 (82) 30.0
Peripheral artery disease 3.5 (18) 10.2
Chronic heart failure 11.8 (60) 25.3
Chronic inflammatory airway disease 5.9 (30) 10.4
Antithrombotic medication prior to admission; % (n)
None 70.1 (357) 59.4
Antiplatelets 24.0 (122) 36.1
Anticoagulation INR < 2 2.8 (14) 2.4
Anticoagulation INR≥ 2† 3.1 (16) 2.1
NIHSS$ on admission (per point); median (IQR) 3.0 (1–7) 7.0
Thrombolysis; % (n) 5.9 (30) 8.1
*OR are related to age in decades; †or full-dose heparin (n = 5); $National Institutes ofindependent risk factor for mortality, extending the
current knowledge on the role of CIAD as relevant co-
morbidity after ischemic stroke (see Table 3). By contrast,
other cardiovascular risk factors such as age, peripheral ar-
tery disease and stroke severity on hospital admission were
confirmed as significant risk factors for short-term as well
as long-term mortality [22–24] or risk factors for more se-
vere stroke, respectively (Table 4) [25]. Interestingly, there
was no significant impact of CIAD on outcome in patients
with TIA but the number of TIA patients with CIAD was
too low to draw final conclusions. Further studies are
needed to validate the impact of CIAD on mortality after
ischemic stroke.
CIAD and ischemic stroke are both primarily affecting
the elderly and have a variety of risk factors in common.
Therefore, a relevant proportion of patients suffer from
both diseases. The observed CIAD prevalence of 7 % in
stroke patients is higher compared to a Swedish cohort
study (3.3 %), and higher compared to the general popu-
lation (0.8 - 3.6 %) [8, 26].
According to current guidelines, CIAD is not consid-
ered a relevant co-morbidity to be addressed for primary
or secondary stroke prevention [27, 28]. Our data on the
long-term course after stroke underline that a relevant
interaction between CIAD and stroke exists, as reported
previously [4, 8, 14]. Notably, this interaction was not
observed in the acute and subacute phase but emergedts with acute ischemic stroke (n = 892). Median follow-up was
Multivariable analysis
th n = 383 p value Probability death HR (95 % CI) p value
(68.0–83.0) <0.001 1.70 (1.53–1.87)* <0.001
(196) 0.065
(115) 0.002 1.16 (0.92–1.46) 0.210
(157) <0.001 1.08 (0.85–1.37) 0.523
(138) <0.001 1.19 (0.96–1.48) 0.108
(293) 0.079
(115) <0.001 1.26 (0.99–1.60) 0.053
(39) <0.001 1.91 (1.35-2.71) <0.001
(97) <0.001 1.13 (0.87–1.45) 0.361
(40) 0.010 1.43 (1.02–2.00) 0.036
(227)
(138) <0.001 1.18 (0.94–1.48) 0.164
(9) 0.786 0.94 (0.47–1.86) 0.858
(8) 0.512 0.59 (0.29–1.12) 0.153
(3–13) <0.001 1.08 (1.06–1.10) <0.001
(31) 0.034 0.922
Health Stroke Scale. Bold indicates significant results
Table 4 Multivariable Cox-regression analysis of characteristics
associated with mortality in patients with acute ischemic stroke
during short-term follow-up (n = 892). Data are expressed as
hazard ratios (95 % CI). All significant characteristics according
to bivariate analyses (as similarly demonstrated in Table 3) were
included. Analyses were adjusted for previous stroke or TIA,
atrial fibrillation, diabetes, chronic heart failure, coronary artery
disease, antithrombotic medication prior to admission, and
thrombolysis)
HR (95 % CI)
30 days 90 days
Age per decade 1.73 (1.39–2.17) 1.89 (1.54–2.31)
Peripheral artery disease 3.27 (1.67–6.42) 3.73 (2.08–6.70)
Chronic inflammatory airway disease 1.51 (0.76–3.01) 1.47 (0.77–2.82)
NIHSS* on admission (per point) 1.22 (1.18–1.26) 1.19 (1.16–1.23)
*National Institutes of Health Stroke Scale score
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concluded that the CIAD related pathophysiologic sig-
nals are subtle and hence may not have a relevant im-
pact on the acute processes after stroke. In the chronic
course after stroke, however, the cumulative impact of
the comorbidity adds to the overall pathophysiologic
burden and results in the observed increase in mortality.
It may by hypothesized that the observed increase in
long-term mortality in these patients is not merely rela-
tive to the CIAD itself as isolated condition but rather
results from an interaction between the two diseases. Fur-
ther studies are needed to uncover the pathophysiologic
links and pathways underlying this interaction between
cerebrovascular disease and systemic inflammation. This
interaction between both co-morbidities seems highly
relevant for the clinical evaluation of these patients [7].
Even more, as CIAD is a systemic inflammatory – yet
treatable – disease and may therefore represent an add-
itional risk factor for ischemic stroke [8, 11] and stroke-
related morbidity. Hence, diagnosing and treating CIAD
appears especially relevant in stroke patients. Prospective
clinical studies (especially in patients with prior stroke) are
needed to confirm whether optimal treatment of CIAD
might reduce the burden of (recurrent) stroke, as sug-
gested for major adverse cardiovascular events in the clin-
ical database of placebo-controlled roflumilast chronic
obstructive pulmonary disease trials [29] or recurrent
stroke in montelukast-treated patients in a Swedish
population-based cohort study [30].
Furthermore, our findings may reflect the importance of
CIAD-related mortality. During the natural history of
CIAD, patients initially die of cardiovascular causes or can-
cer but with advanced CIAD, respiratory failure and lung
related mortality becomes more important [12, 16, 31, 32].
There are several limitations of the study that should
be addressed: First, our study is a post hoc analysis thatsuffers from typical limitations of such studies. Several
variables of interest were not recorded and were, there-
fore, not accessible for analysis. We do, for example, not
have the information on the prevalence of obstructive
sleep apnea. Furthermore, this study does not allow
stratifying for symptomatic severity of CIAD - making it
impossible to do a dose–response analysis -, subsequent
functional impairment or medication schemes. Notably,
unawareness of chronic diseases immediately after acute
ischemic stroke may have resulted in underreporting of
CIAD to a certain extent [33], thus creating a potential
selection bias.
Conclusion
In contrast to other cardiovascular risk factors, CIAD
did not significantly interfere with severity of acute is-
chemic stroke on hospital admission and with short-
term mortality after stroke. Compared to stroke patients
without CIAD, co-existing CIAD increased the hazard of
dying over longer term, suggesting the relevance of
CIAD as a risk factor for patients after ischemic stroke.
This finding underscores the need to identify and man-
age CIAD in those patients with acute ischemic stroke.
It remains to be determined whether the incidence of re-
current stroke in CIAD patients is increased. This
should be investigated in future studies.
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